Granules India Limited , a vertically integrated pharmaceutical company, has announced significant changes in its senior management team, effective November 2025. The company has appointed Vinodkumar Parur as the new Chief Human Resources Officer (CHRO), while the current CHRO, Atul Dhavle, is set to depart.

New CHRO Appointment

Vinodkumar Parur will assume the role of Chief Human Resources Officer at Granules India Limited, effective November 17, 2025. With this appointment, Parur will also be designated as Senior Management Personnel within the organization.

Parur brings over 24 years of extensive HR leadership experience across various sectors, including manufacturing, engineering, pharmaceuticals, and infrastructure. His impressive career includes senior roles at prominent companies such as RR Kabel Limited and Nilkamal Limited.

Professional Background

Vinodkumar Parur's expertise spans several critical areas of human resources management:

• HR function setup for IPO preparation
• Mergers and acquisitions
• Implementation of HRMS systems
• Leadership development
• Employee engagement programs

Prior to joining Granules India, Parur held the position of Chief Human Resources Officer at both RR Kabel Limited and Nilkamal Limited. He has also served in senior HR leadership roles at A.T.E. Group and Schindler India.

Educational Qualifications

Parur holds a master's degree in management studies (Human Resources) from PIMSR, Mumbai University, and a bachelor's degree in commerce and economics from NMIMS, Mumbai University. His educational background is complemented by certifications in various HR assessment and training programs.

Current CHRO's Departure

Atul Dhavle, the current Chief Human Resources Officer of Granules India Limited, has tendered his resignation to explore other opportunities. Dhavle will cease to be Senior Management Personnel effective November 16, 2025. To ensure a smooth transition, he will serve a notice period, during which he will assist in handing over his responsibilities.

Company's Perspective

Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited, expressed confidence in the new appointment: "We are pleased to welcome Vinodkumar Parur to our senior management team. His extensive experience and expertise in human resources management across various industries will be invaluable as we continue to grow and develop our workforce."

The leadership changes come at a time when Granules India is focusing on operational excellence and long-term value creation. The company recently reported a 34% year-on-year growth in revenue from operations for Q2 FY26, reaching INR 12,970.00 million, with a 37% increase in EBITDA to INR 2,782.00 million.

These management changes are expected to support Granules India's ongoing efforts in talent management and organizational development as the company continues to strengthen its position in the pharmaceutical industry.

Granules India Limited has achieved a significant milestone in its expansion strategy, securing its first U.S. Food and Drug Administration (FDA) approval for its Hyderabad facility. This regulatory green light marks a crucial step forward in the company's efforts to enhance its finished dosage production capabilities and strengthen its position in the U.S. pharmaceutical market.

Key Highlights

• Facility Approval: Granules Life Sciences Private Limited (GLS), a wholly-owned subsidiary of Granules India, received FDA approval for its Hyderabad facility (FEI: 3030495702).
• Inspection Details: The approval follows a Pre-Approval Inspection (PAI) conducted between July 28 and August 1, which resulted in one observation. GLS promptly responded within the stipulated timeframe.
• Product Launch: The company plans to introduce the approved product in the U.S. market soon, leveraging this new manufacturing site.
• Strategic Advantage: This approval enables multi-site manufacturing, supporting business continuity and potentially increasing market share for the approved product.

Implications for Granules India

The FDA approval for the Hyderabad facility is expected to have several positive implications for Granules India:

1. Expanded Manufacturing Capabilities: The approval enhances the company's ability to produce finished dosage forms, complementing its existing vertically integrated pharmaceutical manufacturing operations.
2. Market Share Growth: With the ability to manufacture the approved product at multiple sites, Granules India is well-positioned to strengthen its market presence in the U.S.
3. Future Approvals: The company has filed for approval of other products from this site, indicating potential for further expansion of its U.S. market portfolio.

Management Commentary

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited, expressed optimism about the approval, stating, "We plan on launching the product into the U.S. market soon. It is an already approved product at our Gagillapur facility, but we plan on building market share with this approval."

Company Overview

Granules India Limited, established in 1991, has positioned itself as a vertically integrated pharmaceutical company with a global presence. The company's operations span the entire pharmaceutical value chain, including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs).

This FDA approval for the Hyderabad facility underscores Granules India's commitment to operational excellence and quality, potentially paving the way for enhanced market opportunities and sustained growth in the competitive pharmaceutical landscape.